Literature DB >> 27539794

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.

David J Iberri1,2, Bernice Y Kwong3, Laurel A Stevens3, Steven E Coutre1, Jinah Kim4, Jean M Sabile2, Ranjana H Advani2.   

Abstract

Entities:  

Keywords:  ibrutinib; new leukaemia drugs; new lymphoma drugs; skin toxicity

Mesh：

Substances：

Year:  2016        PMID： 27539794     DOI： 10.1111/bjh.14302

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  11 in total

Review 1.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 2.  Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions.

Authors:  Katarzyna Szklener; Adam Michalski; Klaudia Żak; Michał Piwoński; Sławomir Mańdziuk
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

Review 3.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

4.  Ibrutinib-Associated Skin Toxicity: A Case of Maculopapular Rash in a 79-Year Old Caucasian Male Patient with Relapsed Waldenstrom's Macroglobulinemia and Review of the Literature.

Authors:  Anders Bisgaard Jensen; Birgitte Stausbøl-Grøn; Rikke Riber-Hansen; Francesco d'Amore
Journal:  Dermatol Reports       Date:  2017-04-20

5.  Ibrutinib-induced acute kidney injury via interstitial nephritis.

Authors:  Csilla Markóth; Ibolya File; Róbert Szász; László Bidiga; József Balla; János Mátyus
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

Review 6.  The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.

Authors:  Tadeusz Robak; Magda Witkowska; Piotr Smolewski
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639

7.  Palpable purpuric eruption mimicking vasculitis following avapritinib.

Authors:  Taha Osman Mohammed; Sara Malik; Shahzeb Hassan; Zachary Solomon; Jennifer N Choi
Journal:  JAAD Case Rep       Date:  2022-02-14

8.  Ibrutinib-associated pityriasis rosea-like rash.

Authors:  Carole Bitar; Azeen Sadeghian; Lacey Sullivan; Andrea Murina
Journal:  JAAD Case Rep       Date:  2017-12-19

9.  Multifocal periungual granulation tissue related to ibrutinib therapy.

Authors:  Aatman Shah; Anneli Bowen; Christopher Hansen
Journal:  JAAD Case Rep       Date:  2020-01-30

10.  Ibrutinib-Induced Skin Rash

Authors:  Sudhir Kirar; Ajay Gogia; Ritu Gupta; Saumyaranjan Mallick
Journal:  Turk J Haematol       Date:  2020-10-15       Impact factor: 1.831
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.